Trial | Study setting | Sample size | Baseline characteristics of patients receiving EGDT | EGDT in the first 6Â hours | Mortality | |||||
---|---|---|---|---|---|---|---|---|---|---|
 |  |  | APACHE II score | Lactate, mmol/l | Source of sepsis | Total fluids, l | Vasopressor therapy, % | Red cell transfusion, % | Inotropic therapy, % | EGDT vs. usual care, % |
Rivers et al. [7] | Single center in USA | 263 | 21.4 ± 6.9 | 7.7 ± 4.7 | 38.5 % lungs, 25.6 % urinary, 35.9 % other | 4.9 ± 2.9 | 27.4 | 64.1 | 13.7 | 44.3 vs. 56.9a (P = 0.03) |
ProCESS [49] | 31 centers in USA | 1,341 | 20.8 ± 8.1 | 4.8 ± 3.1 | 31.9 % lungs, 22.8 % urinary, 45.3 % other | 2.8 ± 1.9 | 54.9 | 14.4 | 8.0 | 21.0 vs. 18.9a (P = 0.83) |
ARISE [50] | 51 centers in Australia and New Zealand | 1,591 | 15.4 ± 6.5 | 6.7 ± 3.3 | 36.5 % lungs, 18.7 % urinary, 44.8 % other | 2.5 ± 1.2 | 66.6 | 13.6 | 15.4 | 18.6 vs. 18.8b (P = 0.90) |
ProMISe [52] | 56 centers in England | 1,251 | 18.7 ± 7.1 | 7.0 ± 3.5 | 36.5 % lungs, 17.3 urinary, 46.2 % other | 2.2 ± 1.4 | 53.3 | 8.8 | 18.1 | 29.5 vs. 29.2b (P = 0.90) |